Search Within

David Chung

Formats
  1. Meeting Abstract (177)
  2. Journal Article (64)
  3. Research Letter (4)
  4. Correspondence (2)
  5. Book Section (1)
  6. Review (1)
Groups
  1. Bone Marrow Transplant (249)
  2. Center for Hematologic Malignancies (249)
  3. Department of Medicine (249)
  4. Hematologic Malignancies, Division of (249)
  5. Survivorship Research (221)
  6. Myeloma (190)

More Groups

People
  1. Sergio Giralt (208)
  2. Heather Landau (207)
  3. Alexander Lesokhin (175)
  4. Hani Hassoun (166)
  5. Gunjan Shah (156)
  6. Neha Korde (140)

More People

Years
  1. 2025 (4)
  2. 2024 (40)
  3. 2023 (40)
  4. 2022 (34)
  5. 2021 (15)
  6. 2020 (18)

More Years

Publications
  1. Blood (98)
  2. Clinical Lymphoma, Myeloma and Leukemia (44)
  3. Biology of Blood and Marrow Transplantation (28)
  4. Leukemia and Lymphoma (9)
  5. Journal of Clinical Oncology (8)
  6. Transplantation and Cellular Therapy (7)

More Publications

Publishers
  1. American Society of Hematology (103)
  2. Elsevier Inc. (83)
  3. Nature Publishing Group (13)
  4. American Association for Cancer Research (9)
  5. Taylor & Francis Group (9)
  6. American Society of Clinical Oncology (8)

More Publishers

Results (249)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • T cell exhaustion/senescence in relapsed multiple myeloma after autologous stem cell transplantation
    Meeting Abstract

    Chung, D. J.; Pronschinske, K. B.; Shyer, J. A.; Sharma, S.; Leung, S.; Curran, S. A.; Lesokhin, A. M.; Devlin, S.; Giralt, S. A.; Young, J. W.
    Blood (2015)

    Fulltext@MSK | Save
  • Low dose unfractionated heparin (UFH) prophylaxis is a safe strategy for the prevention of hepatic sinusoidal obstruction syndrome (SOS) in adult allogeneic stem cell transplant (HSCT) recipients
    Meeting Abstract

    Bhatt, V.; Palazzo, M.; Kilroy, K.; Hilden, P.; Maloy, M.; Barker, J. N.; Castro-Malaspina, H. R.; Chung, D. J.; Dahi, P. B.; Hsu, K. C.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • Presence of PD-1 expressing T cells predicts for inferior overall survival in newly diagnosed multiple myeloma
    Meeting Abstract

    Gasmi, B.; Smith, E. L.; Dogan, A.; Hsu, M.; Devlin, S.; Pichardo, J. D.; Chung, D. J.; Koehne, G.; Korde, N. S.; Landau, H. J.; more...
    Blood (2015)

    Fulltext@MSK | Save
  • T-cell depleted allogeneic hematopoietic stem cell transplantation for patients with relapsed, high-risk multiple myeloma permits long-lasting remissions in the absence of graft-versus-host disease
    Meeting Abstract

    Koehne, G.; Devlin, S.; Landau, H.; Hassoun, H.; Lesokhin, A.; Lendvai, N.; Chung, D.; Giralt, S.
    Bone Marrow Transplantation (2015)

    Fulltext@MSK | Save
  • Gain of chromosome 1q portends worse prognosis in multiple myeloma patients treated with novel agent based induction regimens even after autologous transplantation
    Meeting Abstract

    Shah, G. L.; Landry, C.; Londono, D.; Devlin, S.; Kosuri, S.; Lesokhin, A. M.; Lendvai, N.; Hassoun, H.; Chung, D. J.; Koehne, G.; more...
    Biology of Blood and Marrow Transplantation (2015)

    Fulltext@MSK | Save
  • Interim analysis of a randomized phase II trial comparing continuous lenalidomide and dexamethasone to autologous stem cell transplantation in multiple myeloma patients responsive to lenalidomide and dexamethasone induction
    Meeting Abstract

    Weltz, J. I.; Landau, H.; Lendvai, N.; Chung, D. J.; Lesokhin, A. M.; Devlin, S. M.; Riedel, E.; Woo, K. M.; Stellman, A.; Chimento, D.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Efficacy and risk factors analysis of upfront autologous stem cell mobilization using plerixafor and granulocyte-colony stimulating factor (GCSF) in patients with multiple myeloma
    Meeting Abstract

    Ogunniyi, A.; Rodriguez, M.; Devlin, S. M.; Adel, N. G.; Landau, H.; Chung, D. J.; Lendvai, N.; Lesokhin, A. M.; Landgren, O.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Analysis of VDT-PACE utilization in multiple myeloma patients treated at MSKCC for relapsed disease or cytoreduction and stem cell mobilization after initial induction therapy
    Meeting Abstract

    Beyer, K.; Rosner, S.; Woo, K. M.; Devlin, S. M.; Landau, H.; Hassoun, H.; Lendvai, N.; Chung, D. J.; Adel, N. G.; Puto, M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Upfront plerixafor plus G-CSF versus cyclophosphamide plus G-CSF for autologous stem cell mobilization in multiple myeloma patients: An update on cost analysis study at Memorial Sloan Kettering Cancer Center
    Meeting Abstract

    Afifi, S.; Adel, N. G.; Duck, E.; Devlin, S. M.; Landau, H.; Lendvai, N.; Lesokhin, A. M.; Chung, D. J.; Landgren, O.; Giralt, S. A.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A phase 2 single-center study of carfilzomib 56 mg/m2 with or without low-dose dexamethasone in relapsed multiple myeloma
    Journal Article

    Lendvai, N.; Hilden, P.; Devlin, S.; Landau, H.; Hassoun, H.; Lesokhin, A. M.; Tsakos, I.; Redling, K.; Koehne, G.; Chung, D. J.; more...
    Blood (2014)

    Fulltext@MSK | Save